http://www.pharmaceuticalmarkets.com/ dipesh_hirani@byteart.com (Dipesh Hirani) http://cyber.law.harvard.edu/rss/rss.html http://www.pharmaceuticalmarkets.com/graphics/logo.gifhttp://www.pharmaceuticalmarkets.com/ 60 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=231 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=231 Investors are turning their attention to antiviral drug discovery because there is a renewed (John Doe1) Tue, 07 Oct 2008 10:37:08 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=232 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=232 The key growth driver for vaccines is their costeffectiveness in combating disease. (John Doe2) Mon, 06 Oct 2008 10:38:08 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=233 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=233 Investors are turning their attention to antiviral drug discovery because there is a renewed (John Doe3) Mon, 06 Oct 2008 10:37:08 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=234 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=234 The key growth driver for vaccines is their costeffectiveness in combating disease. (John Doe4) Sat, 27 Sep 2008 10:37:08 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=235 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=235 Investors are turning their attention to antiviral drug discovery because there is a renewed (John Doe5) Fri, 26 Sep 2008 10:37:08 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=236 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=236 Investors are turning their attention to antiviral drug discovery because there is a renewed (pharmaceuticalmarkets) Mon, 23 Feb 2009 10:16:29 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=238 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=238 The key growth driver for vaccines is their costeffectiveness (pharmaceuticalmarkets) Tue, 24 Feb 2009 10:16:33 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=240 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=240 Investors are turning their attention to antiviral drug discovery because there is a renewed (pharmaceuticalmarkets) Tue, 24 Feb 2009 10:16:36 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=242 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=242 The key growth driver for vaccines is their costeffectiveness (pharmaceuticalmarkets) Tue, 24 Feb 2009 10:16:38 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=244 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=244 Investors are turning their attention to antiviral drug discovery because there is a renewed (pharmaceuticalmarkets) Tue, 24 Feb 2009 10:16:40 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=246 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=246 Investors are turning their attention to antiviral drug discovery because there is a renewed (pharmaceuticalmarkets) Mon, 23 Feb 2009 10:16:29 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=247 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=247 The key growth driver for vaccines is their costeffectiveness (pharmaceuticalmarkets) Tue, 24 Feb 2009 10:16:33 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=248 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=248 Investors are turning their attention to antiviral drug discovery because there is a renewed (pharmaceuticalmarkets) Tue, 24 Feb 2009 10:16:36 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=249 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=249 The key growth driver for vaccines is their costeffectiveness (pharmaceuticalmarkets) Tue, 24 Feb 2009 10:16:38 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=250 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=250 Investors are turning their attention to antiviral drug discovery because there is a renewed (pharmaceuticalmarkets) Tue, 24 Feb 2009 10:16:40 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=253 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=253 Barack Obama has announced new plans to save a further $313 billion for health care reform over the next 10 years, including $75 billion cuts in the prices paid by Medicare for prescription drugs, pharmatimes.com reports. (pharmaceuticalmarkets) Mon, 15 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=254 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=254 Britain will invest $485 million in an international scheme to encourage pharma firms to develop vaccines against some of the common diseases which plague poorer nations, Reuters reports. (pharmaceuticalmarkets) Mon, 15 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=255 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=255 Pfizer has said that it is seeking acquisitions in emerging markets and the Middle East, and forecasts annual 'double-digit growth' in the region in the next five years, Bloomberg reports. (pharmaceuticalmarkets) Mon, 15 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=256 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=256 US regulators said on Friday that Merck's Singulair and similar medicines should come with a caution about reports of psychiatric problems in some patients, Reuters reports. (pharmaceuticalmarkets) Mon, 15 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=257 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=257 Novartis has defied the WHO and some of its corporate peers by ruling out a donation to the poor of vaccines to counter the latest flu pandemic, and said developing nations or donor nations should cover the costs, the FT reports on its website. (pharmaceuticalmarkets) Mon, 15 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=258 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=258 Boehringer Ingelheim said on Monday that it has signed a deal worth up to $242 million with US biotech company Vitae to research and develop new Alzheimer's drugs, Reuters reports. (pharmaceuticalmarkets) Tue, 16 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=259 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=259 Novartis' Sandoz unit was sued by J&J to stop it from selling a copy of the Ortho Tri-Cyclen LO birth-control pill, Bloomberg reports. (pharmaceuticalmarkets) Tue, 16 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=260 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=260 GSK took another step in building its business in emerging markets on Monday by signing an alliance with Indian generic drug maker Dr Reddy's, Reuters reports. (pharmaceuticalmarkets) Tue, 16 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=261 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=261 GSK has responded to the WHO's decision to raise the pandemic level by increasing its vaccine production, hayspharma.com reports. (pharmaceuticalmarkets) Tue, 16 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=262 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=262 GSK and Genmab said on Tuesday that US officials have delayed the deadline by which they expect to rule on their leukaemia treatment Arzerra by three months, Reuters reports. (pharmaceuticalmarkets) Tue, 16 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=263 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=263 Watson said on Wednesday that it will buy privately held Arrow for $1.75 billion, clinching a long-expected deal by the US generic drug maker to expand internationally, Reuters reports. (pharmaceuticalmarkets) Wed, 17 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=264 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=264 Germany's Institute for Quality and Efficacy in Health Care (IQWiG) has accused Pfizer of deliberately withholding data on its antidepressant reboxetine (Edronax), fiercepharma.com reports. (pharmaceuticalmarkets) Wed, 17 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=265 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=265 Amgen's CMO believes its experimental bone drug, denosumab, works at least as well as Zometa to reduce the risk of fractures in cancer patients and some data suggests it could well be superior, Reuters reports. (pharmaceuticalmarkets) Wed, 17 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=266 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=266 Merck and Roche have said that they will work with Adimab on two separate projects which are both aimed at increasing knowledge of antibodies and finding new ones, hayspharma.com reports. (pharmaceuticalmarkets) Wed, 17 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=267 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=267 J&J said on Wednesday that it has joined with the non-profit Global Alliance for TB Drug Development to speed commercialisation of its experimental tuberculosis drug, known as TMC207, Reuters reports. (pharmaceuticalmarkets) Wed, 17 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=268 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=268 Novartis said on Thursday that US regulators have approved its Ilaris to treat children and adults with a rare but potentially fatal auto-inflammatory disease, Reuters reports. (pharmaceuticalmarkets) Thu, 18 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=269 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=269 Ipsen and Pharnext have signed a research, development and marketing agreement covering drug candidates intended for the Charcot Marie-Tooth disease, fiercebiotech.com reports, citing BioWorld. (pharmaceuticalmarkets) Thu, 18 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=270 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=270 Arena has gained a commitment of $100 million in funding from healthcare investors Deerfield Management, fiercebiotech.com reports. (pharmaceuticalmarkets) Thu, 18 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=271 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=271 Teva may rethink where it produces generic drugs as a rally in the shekel increases production costs, Bloomberg reports. (pharmaceuticalmarkets) Thu, 18 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=272 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=272 Sanofi-Aventis has pledged to donate 100 million doses of its swine flu vaccine to developing countries following the escalation of the virus to a pandemic, the FT reports on its website. (pharmaceuticalmarkets) Thu, 18 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=273 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=273 The success of Pfizer's open offer for Pfizer India appears to be bleak, with the stock price of the Indian subsidiary quoting higher than the offer price, India's Economic Times reports on its website. (pharmaceuticalmarkets) Fri, 19 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=274 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=274 US drug reviewers have recommended additional study of delayed development reported in children of mothers who took Abbott's anti-seizure drug Depakote, Reuters reports. (pharmaceuticalmarkets) Fri, 19 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=275 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=275 Sanofi-Aventis said on Thursday that a US court ruled against the company by granting summary judgment motions brought by generic drug makers in patent litigation over the cancer drug Eloxatin, Reuters reports. (pharmaceuticalmarkets) Fri, 19 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=276 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=276 GSK is struggling to build sales of its year-old migraine medicine Treximet as doctors and insurers object to the cost, calling the pill no better than the two generic drugs it combines, Bloomberg reports. (pharmaceuticalmarkets) Fri, 19 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=277 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=277 AstraZeneca cannot block testimony by a medical expert that its antipsychotic Seroquel can cause weight gain and diabetes, a federal judge has ruled, Bloomberg reports. (pharmaceuticalmarkets) Fri, 19 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=278 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=278 Merck and Schering-Plough said on Monday that they had each received requests from US antitrust regulators for more information on their proposed blockbuster merger, Reuters reports. (pharmaceuticalmarkets) Mon, 22 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=279 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=279 A legal battle between Pfizer and Sun has escalated, India's Economic Times reports on its website. (pharmaceuticalmarkets) Mon, 22 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=280 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=280 Merck has moved its experimental cancer vaccine Stimuvax into the third and last phase of testing required for regulatory approval to investigate its use against breast cancer, Reuters reports. (pharmaceuticalmarkets) Mon, 22 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=281 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=281 Men in the UK will be able to buy Viagra on the High Street for the first time instead of going to a doctor after Boots launched a nationwide scheme on Friday, AFP reports. (pharmaceuticalmarkets) Mon, 22 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=282 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=282 NeurogesX has said that it has entered into a marketing deal with the European unit of Astellas, allowing Astellas to sell NeurogesX's dermal patch, Qutenza, in the European Economic Area, the Middle East and Africa, Reuters reports. (pharmaceuticalmarkets) Mon, 22 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=283 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=283 GSK has signed a deal with Chroma, giving it access to the unlisted British biotech company's experimental compounds for inflammatory diseases such as rheumatoid arthritis, Reuters reports. (pharmaceuticalmarkets) Tue, 23 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=284 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=284 SK's CEO, Andrew Witty, has said that morale was terrible in the company's troubled and unproductive R&D department when he took over, fiercebiotech.com reports. (pharmaceuticalmarkets) Tue, 23 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=285 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=285 Abbott said on Tuesday that European regulators approved a new, more flexible version of its Xience drug-eluting stent that is designed for easier placement in the diseased coronary artery, Reuters reports. (pharmaceuticalmarkets) Tue, 23 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=286 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=286 Merck said on Monday that it has entered a partnership with Drugs for Neglected Disease initiative and will licence to the institute drug candidates for tropical diseases that have no cure, or for which treatment could be improved, AP reports. (pharmaceuticalmarkets) Tue, 23 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=287 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=287 A coalition of 15 US states have filed a complaint in federal court charging that Wyeth avoided paying millions of dollars of rebates to state Medicaid programmes that had purchased its Protonix drugs, Massachusetts Attorney General Martha Coakley said on Monday, Reuters reports. (pharmaceuticalmarkets) Tue, 23 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=288 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=288 The head of the FTC said on Tuesday that consumers, insurance companies and the federal government spend an extra $3.5 billion for prescription drugs every year because brand-name companies pay generic producers to stay out of the market, Reuters reports. (pharmaceuticalmarkets) Wed, 24 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=289 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=289 LabCorp has struck a deal to buy Monogram for $106.7 million, a deal that will give the company a new set of tools used in drug discovery work, fiercebiotech.com reports. (pharmaceuticalmarkets) Wed, 24 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=290 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=290 Takeda has finalised a deal to buy the drug maker IDM Pharma in a deal worth more than $50 million (GBP30.2 million), hayspharma.com reports. (pharmaceuticalmarkets) Wed, 24 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=291 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=291 The ex-Pfizer sales manager sentenced for off-label promotion of the Bextra painkiller told Massachusetts officials that the company not only knew about her off-label activities, but encouraged them, fiercepharma.com reports. (pharmaceuticalmarkets) Wed, 24 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=292 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=292 The FDA has said that it will not approve GSK's experimental nausea drug Rezonic for cancer or surgical patients, the drug maker said on Tuesday, Reuters reports. (pharmaceuticalmarkets) Wed, 24 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=293 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=293 Novartis said on Wednesday that a combination of two drugs from Novartis cut the size of pancreatic neuroendocrine tumours in more than 80 per cent of patients in a mid-stage study, Reuters reports. (pharmaceuticalmarkets) Thu, 25 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=294 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=294 Faes has said that it is in talks with Pfizer with regards to a possible link-up for the Spanish firm's investigational oral allergy drug bilastine, pharmatimes.com reports. (pharmaceuticalmarkets) Thu, 25 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=295 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=295 Pfizer's Sutent delayed the worsening of a type of pancreatic cancer by more than five months longer than a placebo, according to data from a clinical trial, Reuters reports. (pharmaceuticalmarkets) Thu, 25 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=296 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=296 The National Institute for Health and Clinical Excellence (NICE) has published final guidance rejecting the use of Merck's Erbitux for recurrent and/or metastatic head and neck cancer, pharmatimes.com reports. (pharmaceuticalmarkets) Thu, 25 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=297 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=297 Japanese regulators have approved a human growth hormone from Novartis, the first approval in Japan for a biosimilar or generic version of a biotech drug, Reuters reports. (pharmaceuticalmarkets) Thu, 25 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=298 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=298 Novartis said on Friday that European regulators have broadened approval for its bone drug Aclasta to treat osteoporosis caused by steroid treatment in men and postmenopausal women, Reuters reports. (pharmaceuticalmarkets) Fri, 26 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=299 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=299 The FDA said on Thursday that its seizure of all drugs and drug ingredients at a Michigan-based manufacturer could lead to a shortage of a particular type of pain reliever, HealthDay News reports. (pharmaceuticalmarkets) Fri, 26 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=300 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=300 J&J and Schering-Plough said on Friday that their once-monthly drug Simponi has been recommended for approval in Europe to treat moderate to severe rheumatoid arthritis, Reuters reports. (pharmaceuticalmarkets) Fri, 26 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=301 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=301 Bristol-Myers and AstraZeneca said on Thursday that an EU regulatory panel gave a positive recommendation to their type II diabetes drug candidate Onglyza, AP reports. (pharmaceuticalmarkets) Fri, 26 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=302 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=302 UCB said on Friday that EU regulators have approved its Cimzia drug as a treatment for rheumatoid arthritis, Reuters reports. (pharmaceuticalmarkets) Fri, 26 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=303 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=303 Japan's government will provide about JPY75 billion ($786 million) over three years to fund clinical trials for drugs that are unlikely to be profitable for pharma companies, Bloomberg reports, citing the Daily Yomiuri. (pharmaceuticalmarkets) Mon, 29 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=304 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=304 GSK said on Friday that an Irish court has ruled that a key patent protecting its biggest-selling medicine is invalid, Reuters reports. (pharmaceuticalmarkets) Mon, 29 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=305 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=305 Israel is setting up a capital fund of up to ILS1 billion ($255 million) to finance biotech start-up companies, its industry and trade and finance ministries said on Monday, Reuters reports. (pharmaceuticalmarkets) Mon, 29 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=306 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=306 Eisai has demonstrated its confidence in the UK's scientific strength by opening a GBP100 million European centre in Hatfield, the FT reports on its website. (pharmaceuticalmarkets) Mon, 29 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=307 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=307 The governments of Australia, New Zealand, Taiwan and Singapore have bought GSK's Relenza flu treatment since the H1N1 outbreak began in April, a top GSK official said on Monday, Reuters reports. (pharmaceuticalmarkets) Mon, 29 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=308 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=308 A US federal jury has returned a $1.67 billion verdict against Abbott in a patent suit brought by J&J related to arthritis treatments, Reuters reports. (pharmaceuticalmarkets) Tue, 30 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=309 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=309 Pfizer has offered concessions to EU regulators to allay competition concerns over its $60.6 billion bid to buy Wyeth, Bloomberg reports. (pharmaceuticalmarkets) Tue, 30 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=310 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=310 Novartis is in talks to buy parts of Irish peer Elan, including its flagship multiple sclerosis products and its Alzheimer's disease pipeline, Reuters reports, citing the Sunday Times. (pharmaceuticalmarkets) Tue, 30 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=311 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=311 Roche has said that a swine flu patient treated with its Tamiflu drug in Denmark showed resistance to the antiviral medicine for the first time, Bloomberg reports. (pharmaceuticalmarkets) Tue, 30 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=312 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=312 GSK has said that its Asia-Pacific sales could double in five years as growing prosperity boosts demand for better healthcare and as it cuts prices in some Asian countries, Reuters reports. (pharmaceuticalmarkets) Tue, 30 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=313 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=313 Biogen will pay up to $510 million to acquire rights to market Acorda's experimental MS pill outside the US, Bloomberg reports. (pharmaceuticalmarkets) Wed, 01 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=314 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=314 Catalyst and Wyeth have announced that the companies have entered into a worldwide collaboration valued at potentially more than $500 million, fiecebiotech.com. (pharmaceuticalmarkets) Wed, 01 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=315 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=315 Pfizer has said that a late stage trial testing its cancer drug Sutent in advanced colon cancer was discontinued after it was deemed to be no more effective than standard chemotherapy, Reuters reports. (pharmaceuticalmarkets) Wed, 01 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=316 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=316 Novartis has said that it expects the FDA to rule on the company's Menveo meningitis vaccine in early 2010 after the regulator sought more information about the treatment, Reuters reports. (pharmaceuticalmarkets) Wed, 01 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=317 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=317 Abbott plans to appeal a jury's $1.67 billion patent infringement ruling in a case involving two blockbuster drugs that treat rheumatoid arthritis and other immune disorders, AP reports. (pharmaceuticalmarkets) Wed, 01 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=318 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=318 J&J will take an 18.4 per cent stake drug developer Elan with a $1 billion investment, AP reports. (pharmaceuticalmarkets) Thu, 02 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=319 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=319 US health officials on Wednesday ordered Pfizer and GSK to add strong 'black box' warnings on their anti-smoking drugs to highlight the risk of serious mental health problems, including suicidal thoughts, Reuters reports. (pharmaceuticalmarkets) Thu, 02 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=320 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=320 Pfizer and Eisai have decided that they will not lodge an appeal against the National Institute for Health and Clinical Excellence’s (NICE) current guidance for the treatment of Alzheimer's disease, pharmatimes.com reports. (pharmaceuticalmarkets) Thu, 02 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=321 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=321 GSK expanded its emerging markets footprint on Thursday by buying Bristol-Myers' branded generics drugs business in Lebanon, Jordan, Syria, Libya and Yemen for $23.2 million, Reuters reports. (pharmaceuticalmarkets) Thu, 02 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=322 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=322 The FDA said on Wednesday that it is reviewing data on the safety of Lantus, a synthetic insulin made by Sanofi-Aventis, AP reports. (pharmaceuticalmarkets) Thu, 02 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=323 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=323 Pfizer is to update all labelling for its smoking cessation drug Chantix after agreeing with the FDA that more safety information should be included, hayspharma.com reports. (pharmaceuticalmarkets) Fri, 03 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=324 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=324 Graceway said on Thursday that it has agreed to buy two potential acne treatments and an anti-scarring drug candidate from Pfizer, AP reports. (pharmaceuticalmarkets) Fri, 03 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=325 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=325 Eisai has said that it is confident about terminating its collaboration with Pfizer, the Japanese drug maker's marketing partner for Aricept, pharmatimes.com reports. (pharmaceuticalmarkets) Fri, 03 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=326 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=326 Roche's Lucentis improved vision after six months in patients with a blockage in the blood supply to the retina, the company’s Genentech unit said, Bloomberg reports. (pharmaceuticalmarkets) Fri, 03 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=327 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=327 Novo Nordisk said on Friday that its diabetes drug Victoza, a key driver for future sales, has won EC approval for marketing across the EU, Reuters reports. (pharmaceuticalmarkets) Fri, 03 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=328 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=328 Philippine health officials have asked the lower house of Congress for an extra $393 million this year to stockpile on antiviral drug and possible flu vaccines as the new influenza A(H1N1) virus continues to spread rapidly, Reuters reports. (pharmaceuticalmarkets) Mon, 06 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=329 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=329 BiolineRX said on Monday that Ikaria has agreed to pay $285 million for a licence to develop and market its BL-1040 drug for heart attack patients, Reuters reports. (pharmaceuticalmarkets) Mon, 06 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=330 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=330 Novartis may challenge the Indian patent tribunal's verdict that its blood cancer drug Glivec cannot be granted patent protection in the country, livemint.com reports. (pharmaceuticalmarkets) Mon, 06 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=331 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=331 Eli Lilly announced on Monday that it has received a fourth approval from the FDA for Altima, PRNewswire reports. (pharmaceuticalmarkets) Mon, 06 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=332 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=332 Pfizer is to invest EUR11 million into a research and development unit at its Ringaskiddy site in Cork to enhance its manufacturing technology, the Irish Times reports on its website. (pharmaceuticalmarkets) Mon, 06 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=333 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=333 The UN Secretary-General, Ban Ki-moon, said on Monday that the organisation may need more than $1 billion this year to help poor countries fight the global swine flu epidemic, AP reports. (pharmaceuticalmarkets) Tue, 07 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=334 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=334 Lundbeck is to drugs firm LifeHealth for $147 million to gain access to a treatment for a symptom of Huntington's disease, Reuters reports. (pharmaceuticalmarkets) Tue, 07 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=335 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=335 GSK said on Tuesday that its Cervarix is the first product of its kind to show that it protects against the five most common cervical cancer-causing viruses, Reuters reports. (pharmaceuticalmarkets) Tue, 07 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=336 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=336 Novartis has become the first healthcare company to join a malaria consortium which aims to end all deaths caused by the disease in Africa by 2015, hayspharma.com reports. (pharmaceuticalmarkets) Tue, 07 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=337 http://www.pharmaceuticalmarkets.com/News_Item.aspx?nid=337 GSK's slimming pill, Alli, is being investigated amid fears it is linked to liver damage, the Daily Mail reports on its website. (pharmaceuticalmarkets) Tue, 07 Jul 2009 00:00:00 GMT